U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns

The U.S.' move to lock up raw materials and supplies for Pfizer's COVID-19 vaccine could spell trouble for manufacturers working on other shots around the globe.

The world’s largest vaccine maker by volume, Serum Institute of India, sees bottlenecks ahead, thanks to a U.S. law blocking exports of certain materials needed to produce COVID-19 shots. The World Health Organization has also raised flags about a global shortage of raw materials used to turn out the pandemic vaccines, Bloomberg first reported.